临床与病理杂志Issue(6)：970-977,8.DOI:10.3978/j.issn.2095-6959.2015.06.020
非小细胞肺癌患者肿瘤组织中驱动基因的分子病理检测分析
The molecular pathology examination analysis of drive gene change in non-small cell lung cancer
摘要
Abstract
Objective: To investigate the mutations of each subtype ofEGFR gene,KRAS geneALK gene,ROS1 gene, c-Met gene andHer-2 gene in non-small cell lung cancer.Methods: Taqman-ARMS was used to test the tissues in 273 patients of non-small cell lung cancer with paraffin tissueEGFR,KRAS,ALK,ROS1,c-Met andHer-2 gene change.Results: hTe total mutation rate in exons 18 to 21 ofEGFR gene was 36.26% (99/273) in NSCLC. EGFR gene mutation rate were found in exons 18(0, 0/550), 19 (16.12%, 44/273), 20 (4.49%, 15/273), and exon 21 (17.95%, 49/273) in the NSCLC. hTe total double mutation rate among every exon ofEGFR gene was4.49%(12/273); the total mutation rate inKRAS gene was 4.76%(13/273); the total positive rate inALK fusion gene was 9.16%(25/273); the total positive rate inROS1fusion gene was 2.20%(6/273); the total ampliifcation rate inc-Met gene was 3.66%(10/273) and the total mutation rate inHer-2 gene was 0.73%(2/273). Drive gene double mutations coexist was 11 cases (4.03%), including 2 cases ofEGFR gene mutation andALK fusion gene positive coexist in (0.73%), 3 cases ofEGFR gene andKRAS gene mutation coexist (1.10%), 6 cases ofEGFR gene mutation andc-Met gene ampliifcation coexistence type (2.20%).Conclusion: hTe mutation rate ofEGFR gene is high in NSCLC patients especially in 19 and 21 exons andALK fusion gene, and the subtype mutations can guide the precision medical for individualized target therapy. hToughKRAS,ROS1,c-Met andHer-2 gene change are low in NSCLC patients, they should not be ignored.关键词
Taqman-ARMS方法/非小细胞肺癌/驱动基因/突变率Key words
Taqman-ARMS method/non-small cell lung cancer/drive gene/mutation rate引用本文复制引用
宋业颖,许春伟,吴永芳,班怡,张博,邵云,李晓兵..非小细胞肺癌患者肿瘤组织中驱动基因的分子病理检测分析[J].临床与病理杂志,2015,(6):970-977,8.基金项目
军事医学科学院附属医院创新科研基金(ZH-2014-10)。@@@@Tis work was supported by Afliated Hospital of Academy of Military Medical Science Innovation Research Foundation (ZH-2014-10), P. R. China （ZH-2014-10）
